Nutex Health Inc (NUTX)
Official siteHEALTHCARE • MEDICAL CARE FACILITIES • NASDAQ
Market Cap: $1.19B
Last updated: Nov 17, 2026 at 11:06 AM ET
Nutex Health Inc (NUTX) Earnings: Report Dates and Results
Nutex Health (NUTX) is expected to report earnings on Mar 3, 2027. In the quarter ended Sep 30, 2026, Nutex Health reported EPS of $5.71, above the $5.53 estimate. It beat the EPS estimate in 5 of the 8 most recent quarters that had an estimate.
Earnings
Performance (10Y)
Upcoming Estimates
Next Report
NUTX has an expected report date of Mar 3, 2027. Analysts' consensus for the quarter ending Dec 31, 2026 is 272.2% above the $1.62 reported for the quarter ended Dec 31, 2025.
NUTX Earnings Call
The latest NUTX earnings call transcript on file is labeled 2026Q3.
Read the 2026Q3 transcriptEarnings History
Of the 13 quarters below that had an estimate, NUTX beat 8, missed 4 and matched 1. Revenue for the quarter ended Sep 30, 2026 was $217.61M, down 18.7% from $267.80M a year earlier.
| Quarter ended | EPS | Estimate | Range | Surprise | Result | YoY | Analysts | Revisions | Reported | Revenue |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep 30, 2026 | $5.71 | $5.53 | $4.71 - $6.56 | +3.25% | Beat | -26.4% | 6 | 5 up, 0 down | Nov 5, 2026 | $217.61M |
| Jun 30, 2026 | $9.58 | $5.26 | $2.87 - $5.58 | +82.13% | Beat | +83.3% | 5 | 2 up, 0 down | Aug 6, 2026 | $210.75M |
| Mar 31, 2026 | $5.74 | $5.56 | $5.56 - $5.56 | +3.24% | Beat | +222.5% | 1 | 0 up, 0 down | Apr 30, 2026 | $216.49M |
| Dec 31, 2025 | $1.62 | $5.56 | $2.99 - $7.30 | -70.85% | Miss | -85.4% | 3 | 1 up, 1 down | Mar 5, 2026 | $151.68M |
| Sep 30, 2025 | $7.76 | $1.95 | $1.95 - $1.95 | +297.95% | Beat | N/A | 1 | 1 up, 0 down | Oct 22, 2025 | $267.80M |
| Jun 30, 2025 | $5.23 | -$5.43 | -$5.43 - -$5.43 | +196.25% | Beat | N/A | 1 | 0 up, 1 down | Jun 30, 2025 | $243.99M |
| Mar 31, 2025 | $1.78 | $3.91 | $2.83 - $4.98 | -54.48% | Miss | N/A | 2 | 1 up, 0 down | May 13, 2025 | $211.79M |
| Dec 31, 2024 | $11.12 | -$0.12 | N/A | N/A | N/A | N/A | N/A | 0 up, 0 down | Mar 31, 2025 | $257.62M |
| Sep 30, 2024 | -$0.32 | $0.28 | -$0.76 - $0.28 | -214.29% | Miss | N/A | 2 | 0 up, 0 down | Nov 8, 2024 | $78.80M |
| Jun 30, 2024 | -$0.15 | -$0.29 | -$0.29 - -$0.29 | +48.28% | Beat | N/A | 1 | 0 up, 0 down | Aug 8, 2024 | $76.08M |
| Mar 31, 2024 | -$0.06 | N/A | N/A | N/A | N/A | N/A | N/A | 0 up, 0 down | May 8, 2024 | $67.45M |
| Dec 31, 2023 | -$7.50 | -$0.01 | N/A | N/A | N/A | N/A | 1 | 0 up, 0 down | Mar 28, 2024 | $69.67M |
| Sep 30, 2023 | -$1.25 | -$1.50 | N/A | +16.67% | Beat | N/A | N/A | 0 up, 0 down | Nov 9, 2023 | $62.72M |
| Jun 30, 2023 | -$1.50 | -$1.50 | -$1.50 - $0.00 | 0.00% | In line | N/A | 2 | 0 up, 0 down | Aug 9, 2023 | $58.92M |
| Mar 31, 2023 | -$1.44 | -$3.00 | -$3.00 - -$1.50 | +52.00% | Beat | N/A | 2 | 0 up, 1 down | May 15, 2023 | $56.33M |
| Dec 31, 2022 | -$0.02 | -$0.01 | -$0.02 - -$0.01 | -100.00% | Miss | N/A | 2 | 0 up, 0 down | Mar 2, 2023 | $53.72M |
| Sep 30, 2022 | -$0.65 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Nov 21, 2022 | $28.40M |
| Jun 30, 2022 | -$0.03 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Aug 22, 2022 | $58.05M |
| Mar 31, 2022 | -$0.35 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Apr 1, 2022 | $79.13M |
| Dec 31, 2021 | -$0.10 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Mar 31, 2022 | $148.73M |
| Sep 30, 2021 | -$0.04 | N/A | N/A | N/A | N/A | -100.1% | N/A | N/A | Nov 15, 2021 | $117.97M |
| Jun 30, 2021 | -$0.07 | N/A | N/A | N/A | N/A | -101.0% | N/A | N/A | Aug 16, 2021 | $62.81M |
| Mar 31, 2021 | -$1.23 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Apr 2, 2021 | $2.01M |
| Dec 31, 2020 | -$184.88 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Dec 31, 2020 | $272.83M |
| Sep 30, 2020 | $50.86 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Nov 16, 2020 | $350032 |
| Jun 30, 2020 | $7.33 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Aug 19, 2020 | $378588 |
| Mar 31, 2020 | -$36.22 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Jun 29, 2020 | $465630 |
| Dec 31, 2019 | -$181.10 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Dec 31, 2019 | N/A |
| Sep 30, 2019 | -$0.48 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Nov 19, 2019 | $17592 |
| Jun 30, 2019 | -$112.39 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Aug 19, 2019 | $14387 |
| Mar 31, 2019 | -$146.58 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Apr 16, 2019 | $13532 |
| Dec 31, 2018 | -$360.91 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Dec 31, 2018 | N/A |
| Sep 30, 2018 | -$313.12 | N/A | N/A | N/A | N/A | -107.9% | N/A | N/A | Nov 19, 2018 | $30416 |
| Jun 30, 2018 | -$426.76 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Aug 14, 2018 | $11620 |
| Mar 31, 2018 | -$377.35 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Apr 17, 2018 | $12122 |
| Sep 30, 2017 | $3,956.70 | N/A | N/A | N/A | N/A | +866.3% | N/A | N/A | Nov 20, 2017 | $26964 |
| Jun 30, 2017 | -$2,105.16 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Aug 18, 2017 | $19027 |
| Mar 31, 2017 | -$371.98 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Mar 31, 2017 | N/A |
| Sep 30, 2016 | $409.48 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Sep 30, 2016 | N/A |
| Jun 30, 2016 | -$181.53 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Jun 30, 2016 | N/A |
Annual EPS
EPS for the fiscal year ended Dec 31, 2025 was $16.39, up 54.7% from the year before. It was -$676.24 for the year ended Dec 31, 2014, the oldest of the 9 fiscal years shown.
| Fiscal year ended | EPS | Change |
|---|---|---|
| Dec 31, 2025 | $16.39 | +54.7% |
| Dec 31, 2024 | $10.59 | N/A |
| Dec 31, 2023 | -$11.69 | N/A |
| Dec 31, 2022 | -$1.05 | N/A |
| Dec 31, 2021 | -$1.44 | N/A |
| Dec 31, 2020 | -$162.91 | N/A |
| Dec 31, 2019 | -$440.55 | N/A |
| Dec 31, 2018 | -$976.76 | N/A |
| Dec 31, 2014 | -$676.24 | N/A |
Earnings Calls
The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 8,800 words across 12 speakers.
| Call | Period ending | Words | Speakers | Transcript |
|---|---|---|---|---|
| 2026Q3 | Sep 30, 2026 | 8,799 | 12 | |
| 2026Q2 | Jun 30, 2026 | 7,740 | 10 | |
| 2026Q1 | Mar 31, 2026 | 5,440 | 9 | |
| 2025Q4 | Dec 31, 2025 | 6,271 | 8 | |
| 2025Q2 | Jun 30, 2025 | 6,110 | 10 | |
| 2025Q1 | Mar 31, 2025 | 4,787 | 10 | |
| 2024Q4 | Dec 31, 2024 | 7,752 | 10 | |
| 2024Q3 | Sep 30, 2024 | 6,172 | 8 |
2026Q3 Earnings Call
Opening remarks
Vivian Sanders Moderator Good morning, everyone, and welcome to Nutex Health, Inc.'s Third Quarter 2026 Earnings Call. My name is Vivian Sanders, and I'm happy to serve as your moderator today. We're truly grateful for your participation and your continued interest in our company as we share the highlights of another exceptional quarter. Please note that this call is being recorded for future reference. Joining me this morning are some of our key leaders driving Nutex Health forward: our Chairman and CEO, Dr. Tom Vo; our Chief Financial Officer, Jon Bates; our President, Dr. Warren Hosseinion; and our Chief Operating Officer, Wes Bamburg. Together, they'll provide prepared remarks to give you a comprehensive view of our performance, strategies, and vision, after which we'll open the floor for your questions. Before I turn things over to Dr. Vo, I'd like to take a moment to address a few important points. Today's discussion may include forward-looking statements, which reflect management's current expectations about our future performance. These statements are based on what we know today, but they're subject to risks, uncertainties, and other factors that could cause our actual results to differ from what we'll share. For a deeper dive into these forward-looking statements and the factors that may influence them, I encourage you to review the press release and Form 10-Q filed earlier this week, as well as our various SEC filings. You'll find all the details there. Additionally, we may reference non-GAAP financial measures such as adjusted EBITDA during the call. For those interested in how these metrics reconcile to GAAP standards, please refer to the press release and the Form 10-Q, where we've included that information. With those housekeeping items out of the way, it's my pleasure to hand the call over to Dr. Tom Vo, our Founder and Chief Executive Officer. Dr. Vo, the floor is yours.
Thomas Vo Chairman and CEO Thank you, Vivian, and good morning, everyone. I'm pleased to join you today to review Nutex Health's third quarter 2026 results. It was another strong quarter with solid financial results, steady collections, important reimbursement developments, and continued growth in hospital volumes. I'll start with our financial and operational performance in the first nine months. For the first three quarters of 2026, total revenue reached $644.9 million, an 11% decrease from $723.6 million for the same period in 2025. Adjusted EBITDA decreased 13% from $243 million to $211.4 million for the first three quarters of 2026. Net income attributable to Nutex increased to $152.9 million for the first three quarters of 2026, a 159% increase from $59 million for the same period in 2025.
Frequently Asked Questions About NUTX
When is Nutex Health's next earnings date?
Nutex Health's next earnings report is expected for Mar 3, 2027.
Did NUTX beat earnings estimates last quarter?
Yes. Nutex Health reported EPS of $5.71 for the quarter ended Sep 30, 2026, above the $5.53 estimate, a 3.25% surprise.
What EPS do analysts expect from NUTX next quarter?
The consensus EPS estimate for Nutex Health for the quarter ending Dec 31, 2026 is $6.03 from 7 analysts, with estimates from $5.57 to $6.56.
How often does NUTX beat earnings estimates?
Nutex Health beat the EPS estimate in 5 of the 8 most recent quarters that had an estimate, with an average surprise of +30.40%.
NUTX pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors